Brought to you by 
Promedior gets $12mm through its Series C venture round
01 Apr 2010
Executive Summary
Promedior (developing therapeutics for fibrotic, inflammatory, and autoimmune diseases) has raised $12mm through the closing of its Series C venture round. Forbion Capital Partners led (and contributes a board member) and was joined by current backers Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital, and three other undisclosed investors. Proceeds will be used to move Promedior's lead candidate PRM151 into Phase II for inflammation and fibrotic disease. The company says it has brought in $27mm during the last year.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Promedior gets $12mm through its Series C venture round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice